Trials / Recruiting
RecruitingNCT03621839
New CSF Biomarkers for Alzheimer's Disease
New Diagnosis or Prognosis Biomarkers for Alzheimer's Disease: Biobank of CSF Collected as Part of Differential Diagnosis of Dementia
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50,000 (estimated)
- Sponsor
- Central Hospital, Nancy, France · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Today, the Alzheimer's disease (AD) diagnosis is founded not only on clinical criteria but also on complementary examinations to confirm a physiopathological process of AD. In complex cases, lumbar punction could be necessary in order to measure Aβ peptides and Total and phosphorylated Tau but new biomarkers could be useful. The main objective of this project is to conserve these cerebrospinal fluids, collected in usual practice in order to validate new biomarkers for diagnosis, prognosis or therapeutic following of Alzheimer's disease and other dementia.
Conditions
Timeline
- Start date
- 2013-07-12
- Primary completion
- 2050-12-31
- Completion
- 2050-12-31
- First posted
- 2018-08-09
- Last updated
- 2024-03-06
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03621839. Inclusion in this directory is not an endorsement.